Summary
This metadata record provides details of the data supporting the claims of the related manuscript: “Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer”. The related study sought to identify and characterise new therapeutic opportunities to enhance current standard of care (SoC) chemotherapies that incorporate anthracyclines and anti-metabolite 5-Fluorouracil (5-FU) in triple-negative breast cancer (TNBC) through further modulation of pyrimidine and uracil nucleotide metabolism pathways, hypothesising that this could be achieved through inhibition of the gatekeeper enzyme, deoxyuridine 5’-triphosphate nucleotidohydrolase (dUTPase), as this enzyme functions to prevent uracil misincorporation into DNA. Type of data: cell survival, growth inhibition, DNA damage analysis, apoptosis, nucleotide pool and in vivo data, Western Blot images Subject of data: MDA-MB-231 (human, ATCC HTB-26), MDA-MB-468 (human, ATCC HTB-132); Female Balb/c mice; 4-6 weeks old; purchased from Envigo. Sample size: Groups of 5-6 mice for control and experimental conditions were used. Power calculations were used to determine sample size.
Data access All the data underlying figures 1-8 of the related article, including cell survival, growth inhibition, DNA damage analysis, apoptosis, nucleotide pool and in vivo data, along with data underlying supplementary figures 1, 2, 3, 4, 5, 7, 8 and Western Blot images for supplementary figure 1a-b, are openly available as part of this figshare data record. Data files are named in-line with the figure they underlie, and each may contain multiple tabs for the sub-figures. Corresponding author(s) for this study Melissa J LaBonte, Medicine, Dentistry and Biomedical Sciences: Patrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast, BT9 7AE, UK. el: +44 2890972789; Email: [email protected].
Study approval The mouse work was performed under an approved UK project license and approved by the institutional Queen's University Belfast Animal Welfare Ethical Review Body (AWERB).

Summary
This metadata record provides details of the data supporting the claims of the related manuscript: “Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer”. The related study sought to identify and characterise new therapeutic opportunities to enhance current standard of care (SoC) chemotherapies that incorporate anthracyclines and anti-metabolite 5-Fluorouracil (5-FU) in triple-negative breast cancer (TNBC) through further modulation of pyrimidine and uracil nucleotide metabolism pathways, hypothesising that this could be achieved through inhibition of the gatekeeper enzyme, deoxyuridine 5’-triphosphate nucleotidohydrolase (dUTPase), as this enzyme functions to prevent uracil misincorporation into DNA. Type of data: cell survival, growth inhibition, DNA damage analysis, apoptosis, nucleotide pool and in vivo data, Western Blot images Subject of data: MDA-MB-231 (human, ATCC HTB-26), MDA-MB-468 (human, ATCC HTB-132); Female Balb/c mice; 4-6 weeks old; purchased from Envigo. Sample size: Groups of 5-6 mice for control and experimental conditions were used. Power calculations were used to determine sample size.
Data access All the data underlying figures 1-8 of the related article, including cell survival, growth inhibition, DNA damage analysis, apoptosis, nucleotide pool and in vivo data, along with data underlying supplementary figures 1, 2, 3, 4, 5, 7, 8 and Western Blot images for supplementary figure 1a-b, are openly available as part of this figshare data record. Data files are named in-line with the figure they underlie, and each may contain multiple tabs for the sub-figures. Corresponding author(s) for this study Melissa J LaBonte, Medicine, Dentistry and Biomedical Sciences: Patrick G Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast, BT9 7AE, UK. el: +44 2890972789; Email: [email protected].
Study approval The mouse work was performed under an approved UK project license and approved by the institutional Queen's University Belfast Animal Welfare Ethical Review Body (AWERB).